Enter inventor name

Byung Ho Lee

This inventor holds 12 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignees: Korea Research Institute of Chemical Technology, Dongbu Hannong Chemical Co., Ltd., Schaeffler Technologies Ag & Co .Kg. Active years: 1993-2025.

USPTO Granted Patents = 12 (Patent Applications = 2)

% Patents Active = 58.3

EPO Patents = 2

Average Co-Inventor Count = 5.8

ph-index = 2

Forward Citations = 15(Granted Patents)

Location History:

Pusan, KR (2002)
Taejon-si, KR (2001 - 2008)
Taejeon-si, KR (2008)
Daejeon, KR (1993 - 2012)

Company Filing History:

7 out of 651

Korea Research Institute of Chemical Technology

patents

3 out of 12

Dongbu Hannong Chemical Co., Ltd.

patents

1 out of 3,795

Schaeffler Technologies Ag & Co .Kg

5. 1 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 1993-2025

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12195469 - Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof (2025-01-14),

2. 12187729 - Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof (2025-01-07),

3. 8198307 - Imidazole derivatives having aryl piperidine substituent, method for preparation thereof and pharmaceutical compositions containing same (2012-06-12),

4. 7420060 - Benzopyran derivatives substituted with a thioxobenzoxazole derivative, pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them (2008-09-02),

5. 7351843 - Furancarbonylguanidine derivatives, their preparation and pharmaceutical compositions containing them (2008-04-01),

6. 7309793 - Benzopyran derivatives substituted with a benzimidazole derivative, pharmaceutically acceptable salts therof, their preparations and pharmaceutical compositions containing them (2007-12-18),

7. 6481909 - Appearing and disappearing core type writing utility (2002-11-19),

8. 6413983 - Benzopyranyl heterocycle derivatives, process for preparation thereof, and pharmaceutical compositions containing them (2002-07-02),

9. 6323238 - Benzopyranyl guanidine derivatives, process for preparation thereof, and pharmaceutical compositions containing them (2001-11-27),

10. 5493029 - Certain pyridyl-benzopyran derivatives (1996-02-20),

11. 5300511 - Spiro-benzopyran derivatives and useful for treating asthma and (1994-04-05),

12. 5236935 - Benzopyran derivatives and processes for the preparation thereof (1993-08-17),

Title: Byung Ho Lee: Innovator in PDE9A Inhibitory Compounds

Introduction

Byung Ho Lee is a prominent inventor based in Taejon-si, South Korea. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds with PDE9A inhibitory activity. With a total of 12 patents to his name, Lee's work has the potential to impact the treatment of various diseases.

Latest Patents

Among his latest patents, Lee has developed compounds that exhibit PDE9A inhibitory activity. These compounds are characterized by a specific chemical structure and can be used in pharmaceutical applications. The inventions include compositions containing these compounds or their pharmaceutically acceptable salts. Furthermore, Lee's patents outline methods for treating or preventing PDE9A-related diseases by administering effective amounts of these compounds or compositions to patients in need.

Career Highlights

Lee has worked with notable organizations such as the Korea Research Institute of Chemical Technology and Dongbu Hannong Chemical Co., Ltd. His experience in these institutions has allowed him to refine his expertise in chemical technology and pharmaceutical development.

Collaborations

Some of Lee's notable coworkers include Kyu Yang Yi and Jee Hee Suh. Their collaborative efforts have contributed to the advancement of research in the field of PDE9A inhibitors.

Conclusion

Byung Ho Lee's innovative work in developing PDE9A inhibitory compounds showcases his dedication to advancing pharmaceutical science. His contributions are poised to make a significant impact on the treatment of related diseases.

Profile summary based on public USPTO records.

Please report any incorrect information to [email protected]